Status:
RECRUITING
Comparative Study of Tranexamic Acid Dosing in Cardiac Surgery
Lead Sponsor:
University of Ioannina
Conditions:
Blood Coagulation Disorder
Postoperative Blood Loss
Eligibility:
All Genders
18-99 years
Phase:
NA
Brief Summary
Tranexamic axid is routinely used as an antifibrinolytic agent in cardiac surgery to reduce the risk of blood loss and transfusion. However, there is no consensus regarding the dosage regimen of trane...
Detailed Description
Excessive bleeding and blood transfusions are common in patients undergoing cardiac surgery. Antifibrinolytic therapy reduces the risk of blood loss and transfusion among patients undergoing cardiac s...
Eligibility Criteria
Inclusion
- Patients undergoing elective cardiac surgery using cardiopulmonary bypass
- Patients to have discontinued anticoagulant and antiplatelet therapy preoperatively according to guidelines.
Exclusion
- Age below 18 years
- Patient refusal
- Pregnancy
- End-stage renal disease
- History of epilepsy,
- Cardiac surgery without the use of cardiopulmonary bypass (off-pump)
- Emergency operations
- Known allergy to the administered agents.
Key Trial Info
Start Date :
May 14 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 15 2027
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT07164300
Start Date
May 14 2024
End Date
December 15 2027
Last Update
September 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital of Ioannina
Ioannina, Greece